Revusiran (sodium)
Revusiran sodium is a 1st-generation short interfering RNA, which directed against transthyretin (TTR) mRNA. Revusiran sodium can be used for transthyretin (TTR) -mediated amyloidosis research[1].
Product Specifications
Product Name Alternative
ALN-TTRSC (sodium)
UNSPSC
12352208
Target
Small Interfering RNA (siRNA) ; Transthyretin (TTR)
Type
Oligonucleotides
Related Pathways
Epigenetics; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/revusiran-sodium.html
Purity
93.16
Solubility
10 mM in H2O
Smiles
[Revusiran(sodium)]
Molecular Weight
16121 (free acid)
References & Citations
[1]Jessica E Sutherland, et al. Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis. Nucleic Acid Ther. 2020 Feb;30 (1) :33-49.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Oligonucleotides
Clinical Information
Phase 3
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
032446-PE 200 µL
BCAS2, NT (BCAS2, DAM1, Pre-mRNA-splicing factor SPF27, Breast carcinoma-amplified sequence 2, DNA amplified in mammary carcinoma 1 protein, Spliceosome-associated protein SPF 27) (PE) discontinued
Sign In for Pricing
View Details HY-W545104-01 10 mg
N6-Bz-5'-O-DMTr-3'-deoxyadenosine-2'-O-CED-phosphoramidite
Sign In for Pricing
View Details 
HY-W545104-02 25 mg
N6-Bz-5'-O-DMTr-3'-deoxyadenosine-2'-O-CED-phosphoramidite
Sign In for Pricing
View Details HY-W545104-03 50 mg
N6-Bz-5'-O-DMTr-3'-deoxyadenosine-2'-O-CED-phosphoramidite
Sign In for Pricing
View Details